Resistance to systemic immune checkpoint inhibition in the peritoneal niche

Immune checkpoint inhibition (ICI) is an established therapeutic option for patients with deficient mismatch repair or high levels of microsatellite instability tumors. Yet, response to ICI among this group is varied, with nearly one-third of patients exhibiting primary resistance. Initial efforts i...

Descripción completa

Detalles Bibliográficos
Autores principales: Chia, Daryl Kai Ann, Gwee, Yong Xiang, Sundar, Raghav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214396/
https://www.ncbi.nlm.nih.gov/pubmed/35728873
http://dx.doi.org/10.1136/jitc-2022-004749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214396/
https://www.ncbi.nlm.nih.gov/pubmed/35728873
http://dx.doi.org/10.1136/jitc-2022-004749

Ejemplares similares